Sugi Predict

Sugi Predict / Compounds / SCHEMBL4410166

SCHEMBL4410166

SCHEMBL4410166

CC(C)(C)OC(=O)N1CCN2C(=O)c3ccc(-c4ccccc4)cc3OCC2C1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ USP30 Q70CQ3 11/20 0.51
▸ ABCB1 P08183 1/20 0.42
▸ HDAC6 Q9UBN7 2/20 0.42
▸ EGFR P00533 1/20 0.41
▸ SRC P12931 1/20 0.41
▸ HDAC8 Q9BY41 1/20 0.41
▸ BACE1 P56817 1/20 0.41
▸ SMARCA2 P51531 1/20 0.40
▸ SMARCA4 P51532 1/20 0.40
▸ PBRM1 Q86U86 1/20 0.40
▸ PRMT5 O14744 1/20 0.40
▸ WDR77 Q9BQA1 1/20 0.40
▸ GABRA1 P14867 1/20 0.40
▸ GABRG2 P18507 1/20 0.40
▸ GABRB3 P28472 1/20 0.40
▸ GABRA5 P31644 1/20 0.40
▸ GABRA3 P34903 1/20 0.40
▸ GABRA2 P47869 1/20 0.40
▸ GABRA4 P48169 1/20 0.40
▸ CRBN Q96SW2 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4410917 0.93 USP30 (0.49) USP30ABCB1HDAC6EGFRSRC
SCHEMBL4408213 0.88 USP30 (0.43) USP30ABCB1HDAC6EGFRSRC
SCHEMBL4408792 0.86 TP53 (0.46) USP30ABCB1HDAC6SMARCA2SMARCA4
SCHEMBL30881505 0.85 USP30 (0.48) USP30ABCB1HDAC6EGFRSRC
SCHEMBL4415810 0.85 USP30 (0.42) USP30SMARCA2SMARCA4PBRM1
SCHEMBL4409882 0.85 FPR2 (0.43) USP30HDAC6BACE1SMARCA2SMARCA4
SCHEMBL4411286 0.84 USP30 (0.44) USP30ABCB1HDAC6EGFRSRC
SCHEMBL14480991 0.83 P2RY14 (0.42) USP30HDAC6HDAC8
SCHEMBL14480600 0.83 P2RY14 (0.42) USP30HDAC6HDAC8
SCHEMBL14480601 0.83 P2RY14 (0.42) USP30HDAC6HDAC8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3101013-B1 FUSED BENZOXAZEPINONES AS ION CHANNEL MODULATORS GILEAD SCIENCES INC (US) 2020-10-21 — — EP disclosed
EP-3085694-B1 FUSED BENZOXAZEPINONES AS ION CHANNEL MODULATORS GILEAD SCIENCES INC (US) 2020-03-25 — — EP disclosed
EP-3088395-B1 FUSED BENZOXAZEPINONES AS ION CHANNEL MODULATORS GILEAD SCIENCES INC (US) 2020-03-25 — — EP disclosed
EP-3098218-B1 FUSED BENZOXAZEPINONES AS ION CHANNEL MODULATORS GILEAD SCIENCES INC (US) 2020-03-25 — — EP disclosed
EP-3085696-B1 FUSED BENZOXAZEPINONES AS ION CHANNEL MODULATORS GILEAD SCIENCES INC (US) 2020-03-04 — — EP disclosed
US-9676760-B2 Fused heterocyclic compounds as ion channel modulators GILEAD SCIENCES, INC. (US) 2017-06-13 — — US disclosed
US-9598435-B2 Fused heterocyclic compounds as ion channel modulators GILEAD SCIENCES, INC. (US) 2017-03-21 — — US disclosed
EP-3101013-A1 FUSED BENZOXAZEPINONES AS ION CHANNEL MODULATORS Gilead Sciences, Inc. (US) 2016-12-07 — — EP disclosed
US-20160347744-A1 FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS GILEAD SCIENCES, INC. 2016-12-01 — — US disclosed
EP-3098218-A1 FUSED BENZOXAZEPINONES AS ION CHANNEL MODULATORS Gilead Sciences, Inc. (US) 2016-11-30 — — EP disclosed
EP-3085694-A1 FUSED BENZOXAZEPINONES AS ION CHANNEL MODULATORS Gilead Sciences, Inc. (US) 2016-10-26 — — EP disclosed
EP-3085696-A1 FUSED BENZOXAZEPINONES AS ION CHANNEL MODULATORS Gilead Sciences, Inc. (US) 2016-10-26 — — EP disclosed
US-20160096846-A1 FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS GILEAD SCIENCES, INC. 2016-04-07 — — US disclosed
US-9193694-B2 Fused heterocyclic compounds as ion channel modulators GILEAD SCIENCES, INC. (US) 2015-11-24 — — US disclosed
US-20140135317-A1 FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS GILEAD SCIENCES, INC. (US) 2014-05-15 — — US disclosed
US-8697863-B2 Fused heterocyclic compounds as ion channel modulators GILEAD SCIENCES, INC. (US) 2014-04-15 — — US disclosed
US-8586732-B2 Fused heterocyclic compounds as ion channel modulators GILEAD SCIENCES, INC. (US) 2013-11-19 — — US disclosed
US-20130184255-A1 FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS GILEAD SCIENCES, INC. (US) 2013-07-18 — — US disclosed
US-20130012492-A1 FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS GILEAD SCIENCES, INC. 2013-01-10 — — US disclosed
US-20090318412-A1 Tricyclic heterocyclic compound and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-12-24 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130184255-A1 FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS KCNJ2, HCN4, KCNJ4 USP30 4731/4885ABCB1 459/4885HDAC6 332/4885
US-20090318412-A1 Tricyclic heterocyclic compound and use thereof HTR2C, HTR2A, HTR5A USP30 4369/4885ABCB1 848/4885HDAC6 745/4885
US-20130012492-A1 FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS KCNJ2, HCN4, KCNJ4 USP30 4731/4885ABCB1 459/4885HDAC6 332/4885
US-20160347744-A1 FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS KCNJ2, HCN4, KCNJ4 USP30 4731/4885ABCB1 459/4885HDAC6 332/4885
US-20140135317-A1 FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS KCNJ2, HCN4, KCNJ4 USP30 4731/4885ABCB1 459/4885HDAC6 332/4885
US-20160096846-A1 FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS KCNJ2, HCN4, KCNJ4 USP30 4731/4885ABCB1 459/4885HDAC6 332/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.